MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma

References

• Alcala, N., C. Caux, N. Girard, J. D. D. McKay, F. Galateau-Salle, M. Foll, and L. Fernandez-Cuesta. 2018. Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this disease. bioRxiv 334326.
   Google Scholar
• Andujar, P., A. Lacourt, P. Brochard, J.-C. Pairon, M.-C. Jaurand, and D. Jean. 2016. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. J. Toxicol. Environ. Health B 19:151–72. doi:10.1080/10937404.2016.1193361.
   PubMed Web of Science ®Google Scholar
• Bianchi, C., and T. Bianchi. 2007. Malignant mesothelioma: Global incidence and relationship with asbestos. Ind. Health 45:379–87. doi:10.2486/indhealth.45.379.
   PubMed Web of Science ®Google Scholar
• Bibby, A. C., S. Tsim, N. Kanellakis, H. Ball, D. C. Talbot, K. G. Blyth, N. A. Maskell, and I. Psallidas. 2016. Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment. Eur. Respir. Rev. 25:472–86. doi:10.1183/16000617.0063-2016.
   PubMed Web of Science ®Google Scholar
• Celsi, F., S. Crovella, R. R. Moura, M. Schneider, F. Vita, L. Finotto, G. Zabucchi, P. Zacchi, and V. Borelli. 2019. Pleural mesothelioma and lung cancer: The role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes. J. Toxicol. Environ. Health A 82:1088–102. doi:10.1080/15287394.2019.1694612.
   PubMed Web of Science ®Google Scholar
• Crovella, S., R. R. Moura, S. Cappellani, F. Celsi, E. Trevisan, M. Schneider, A. Brollo, E. M. Nicastro, F. Vita, and L. Finotto. 2018. A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma. J. Toxicol. Environ. Health A 81:98–105. doi:10.1080/15287394.2017.1416911.
   PubMed Web of Science ®Google Scholar
• De Santi, C., O. Melaiu, A. Bonotti, L. Cascione, G. Di Leva, R. Foddis, A. Cristaudo, M. Lucchi, M. Mora, and A. Truini. 2017. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci. Rep. 7:3140. doi:10.1038/s41598-017-02694-0.
   PubMed Web of Science ®Google Scholar
• Denli, A. M., B. B. J. Tops, R. H. A. Plasterk, R. F. Ketting, and G. J. Hannon. 2004. Processing of primary microRNAs by the microprocessor complex. Nature 432:231. doi:10.1038/nature03049.
   PubMed Web of Science ®Google Scholar
• Dodson, R. F. 2016. Preface: Respirable elongated mineral particles and human health—revisited. Taylor & Francis.
   Google Scholar
• Driece, H. A. L., S. Siesling, P. H. J. J. Swuste, and A. Burdorf. 2010. Assessment of cancer risks due to environmental exposure to asbestos. J. Exposure Sci. Environ. Epidemiol. 20:478–85. doi:10.1038/jes.2009.56.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher, A., and F. J. Slack. 2006. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 6:259. doi:10.1038/nrc1840.
   PubMed Web of Science ®Google Scholar
• Flores, R. M., M. Zakowski, E. Venkatraman, L. Krug, K. Rosenzweig, J. Dycoco, C. Lee, C. Yeoh, M. Bains, and V. Rusch. 2007. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J. Thorac. Oncol. 2:957–65. doi:10.1097/JTO.0b013e31815608d9.
   PubMed Web of Science ®Google Scholar
• Frost, G. F. 2013. 273 The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005). Occup. Environ. Med. 70 (Suppl 1):A93–A93. doi:10.1136/oemed-2013-101717.273.
   Google Scholar
• Gao, P., H. Wang, J. Yu, J. Zhang, Z. Yang, M. Liu, Y. Niu, X. Wei, W. Wang, and H. Li. 2018. miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2. PLoS Genet. 14:e1007790. doi:10.1371/journal.pgen.1007790.
   PubMed Web of Science ®Google Scholar
• Guo, L., Y. Bai, S. Ji, and H. Ma. 2019. MicroRNA‑98 suppresses cell growth and invasion of retinoblastoma via targeting the IGF1R/k‑Ras/Raf/MEK/ERK signaling pathway. Int. J. Oncol. 54:807–20. doi:10.3892/ijo.2019.4689.
   PubMed Web of Science ®Google Scholar
• Guo, Y., L. Chen, C. Sun, and C. Yu. 2017. MicroRNA-500a promotes migration and invasion in hepatocellular carcinoma by activating the Wnt/β-catenin signaling pathway. Biomed. Pharmacother. 91:13–20. doi:10.1016/j.biopha.2017.04.018.
   PubMed Web of Science ®Google Scholar
• Hiriart, E., R. Deepe, and A. Wessels. 2019. Mesothelium and malignant mesothelioma. J. Dev. Biol. 7::7. doi:10.3390/jdb7020007.
   PubMed Web of Science ®Google Scholar
• Hmeljak, J., F. Sanchez-Vega, K. A. Hoadley, J. Shih, C. Stewart, D. Heiman, P. Tarpey, L. Danilova, E. Drill, and E. A. Gibb. 2018. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8:1548–65. doi:10.1158/2159-8290.CD-18-0804.
   PubMed Web of Science ®Google Scholar
• Howard, J., and P. Middendorf. 2010. Exposure science can increase protection of workers and their families from exposure to asbestos and inform on the effects of other elongate mineral particles. J. Exposure Sci. Environ. Epidemiol. 20:485–86. doi:10.1038/jes.2010.40.
   PubMed Web of Science ®Google Scholar
• Hu, S., Q. Zheng, H. Wu, C. Wang, T. Liu, and W. Zhou. 2017. miR-532 promoted gastric cancer migration and invasion by targeting NKD1. Life Sci. 177:15–19. doi:10.1016/j.lfs.2017.03.019.
   PubMed Web of Science ®Google Scholar
• Hylebos, M., G. Van Camp, G. Vandeweyer, E. Fransen, M. Beyens, R. Cornelissen, A. Suls, P. Pauwels, J. P. van Meerbeeck, and K. Op de Beeck. 2017. Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. Oncotarget 8:113673. doi:10.18632/oncotarget.v8i69.
   PubMedGoogle Scholar
• Ibrahim, S. A., H. Hassan, and M. Götte. 2014. Micro RNA regulation of proteoglycan function in cancer. Febs J. 281:5009–22. doi:10.1111/febs.2014.281.issue-22.
   PubMed Web of Science ®Google Scholar
• Knights, A. J., A. P. W. Funnell, M. Crossley, and R. C. M. Pearson. 2012. Holding tight: Cell junctions and cancer spread. Trends Cancer Res. 8:61.
   PubMedGoogle Scholar
• Lamberti, M., R. Capasso, A. Lombardi, M. Di Domenico, A. Fiorelli, A. Feola, A. F. Perna, M. Santini, M. Caraglia, and D. Ingrosso. 2015. Two different serum MiRNA signatures correlate with the clinical outcome and histological subtype in pleural malignant mesothelioma patients. PLoS ONE 10:e0135331. doi:10.1371/journal.pone.0135331.
   PubMed Web of Science ®Google Scholar
• Liu, J., W. Chen, Z. Chen, J. Wen, H. Yu, F. Wang, L. Wu, and X. He. 2017. The effects of microRNA-98 inhibits cell proliferation and invasion by targeting STAT3 in nasopharyngeal carcinoma. Biomed. Pharmacother. 93:869–78. doi:10.1016/j.biopha.2017.06.094.
   PubMed Web of Science ®Google Scholar
• LV, Y., H. Yang, X. Ma, and G. Wu. 2019. Strand-specific miR-28-3p and miR-28-5p have differential effects on nasopharyngeal cancer cells proliferations, apoptosis, migration and invasion. Cancer Cell Int. 19: doi:10.1186/s12935-019-0915-x.
   Web of Science ®Google Scholar
• Magnani, C., A. Agudo, C. A. Gonzalez, A. Andrion, A. Calleja, E. Chellini, P. Dalmasso, A. Escolar, S. Hernandez, and C. Ivaldi. 2000. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br. J. Cancer 83:104. doi:10.1054/bjoc.2000.1161.
   PubMed Web of Science ®Google Scholar
• Martínez-Rivera, V., M. Negrete-García, F. Ávila-Moreno, and B. Ortiz-Quintero. 2018. Secreted and tissue miRNAs as diagnosis biomarkers of malignant pleural mesothelioma. Int. J. Mol. Sci. 19:595. doi:10.3390/ijms19020595.
   PubMed Web of Science ®Google Scholar
• Moya, L., J. Meijer, S. Schubert, F. Matin, and J. Batra. 2019. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis. Int. J. Mol. Sci. 20:1154. doi:10.3390/ijms20051154.
   PubMed Web of Science ®Google Scholar
• Munson, P. B., E. M. Hall, N. H. Farina, H. I. Pass, and A. Shukla. 2019. Exosomal miR-16-5p as a target for malignant mesothelioma. Sci. Rep. 9:1–13. doi:10.1038/s41598-019-48133-0.
   PubMed Web of Science ®Google Scholar
• Pan, D. 2010. The hippo signaling pathway in development and cancer. Dev. Cell 19:491–505. doi:10.1016/j.devcel.2010.09.011.
   PubMed Web of Science ®Google Scholar
• Pickup, M. W., J. K. Mouw, and V. M. Weaver. 2014. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15:1243–53. doi:10.15252/embr.201439246.
   PubMed Web of Science ®Google Scholar
• Robinson, B. W. S., and R. A. Lake. 2005. Advances in malignant mesothelioma. N. Engl. J. Med. 353:1591–603. doi:10.1056/NEJMra050152.
   PubMed Web of Science ®Google Scholar
• Röhrig, F., and A. Schulze. 2016. The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 16 (7):32. doi:10.1038/nrc.2016.89.
   Google Scholar
• Sage, A., V. Martinez, B. Minatel, M. Pewarchuk, E. Marshall, G. MacAulay, R. Hubaux, D. Pearson, A. Goodarzi, and G. Dellaire. 2018. Genomics and epigenetics of malignant mesothelioma. High-throughput 7:20. doi:10.3390/ht7030020.
   PubMedGoogle Scholar
• Schipper, H., T. Papp, G. Johnen, H. Pemsel, R. Bastrop, K.-M. Müller, T. Wiethege, M. Jaworska, M. Krismann, and D. Schiffmann. 2003. Mutational analysis of the Nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas. Int. J. Oncol. 22:1009–17.
   PubMed Web of Science ®Google Scholar
• Sekido, Y. 2013. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34:1413–19. doi:10.1093/carcin/bgt166.
   PubMed Web of Science ®Google Scholar
• Sépult, C., M. Bellefroid, N., . Rocks, K. Donati, C. Gérard, C. Gilles, A. Ludwig, B. Duysinx, A. Noël, and D. Cataldo. 2019. ADAM10 mediates malignant pleural mesothelioma invasiveness. Oncogene 38:3521. doi:10.1038/s41388-018-0669-2.
   PubMed Web of Science ®Google Scholar
• Shi, X., and F. Teng. 2015. Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1). Mol. Cell. Biochem. 408:283–93. doi:10.1007/s11010-015-2506-z.
   PubMed Web of Science ®Google Scholar
• Soeberg, M. J., J. Leigh, and N. van Zandwijk. 2016. Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends. J. Toxicol. Environ. Health B 19:173–89. doi:10.1080/10937404.2016.1194254.
   PubMed Web of Science ®Google Scholar
• Spirtas, R., E. F. Heineman, L. Bernstein, G. W. Beebe, R. J. Keehn, A. Stark, B. L. Harlow, and J. Benichou. 1994. Malignant mesothelioma: Attributable risk of asbestos exposure. Occup. Environ. Med. 51:804–11. doi:10.1136/oem.51.12.804.
   PubMed Web of Science ®Google Scholar
• Tang, W., W. Zhou, L. Xiang, X. Wu, P. Zhang, J. Wang, G. Liu, W. Zhang, Y. Peng, and X. Huang. 2019. The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer. Nat Commun 10:663. doi:10.1038/s41467-018-08225-3.
   PubMed Web of Science ®Google Scholar
• Tsiakanikas, P., C. K. Kontos, D. Kerimis, I. N. Papadopoulos, and A. Scorilas. 2018. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. Clin. Chem. Lab. Med. 56:990–1000. doi:10.1515/cclm-2017-0430.
   PubMed Web of Science ®Google Scholar
• van der Bij, S., H. Koffijberg, J. A. Burgers, P. Baas, M. J. Van de Vijver, B. A. J. M. De Mol, and K. G. M. Moons. 2012. Prognosis and prognostic factors of patients with mesothelioma: A population-based study. Br. J. Cancer 107:161. doi:10.1038/bjc.2012.245.
   PubMed Web of Science ®Google Scholar
• Vlachos, I. S., K. Zagganas, M. D. Paraskevopoulou, G. Georgakilas, D. Karagkouni, T. Vergoulis, T. Dalamagas, and A. G. Hatzigeorgiou. 2015. DIANA-miRPath v3. 0: Deciphering microRNA function with experimental support. Nucleic Acids Res. 43:W460–W466. doi:10.1093/nar/gkv403.
   PubMed Web of Science ®Google Scholar
• Walker, C., E. Mojares, and A. Del Río Hernández. 2018. Role of extracellular matrix in development and cancer progression. Int. J. Mol. Sci. 19:3028. doi:10.3390/ijms19103028.
   PubMed Web of Science ®Google Scholar
• Walter, R. F. H., F. D. Mairinger, S. Ting, C. Vollbrecht, T. Mairinger, D. Theegarten, D. C. Christoph, K. W. Schmid, and J. Wohlschlaeger. 2015. MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br. J. Cancer 112:883. doi:10.1038/bjc.2015.27.
   PubMed Web of Science ®Google Scholar
• Wang, F., J. T.-H. Chang, C. J. Kao, and R. Huang. 2016. High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro. Mol. Cancer Ther. 15:1123–31. doi:10.1158/1535-7163.MCT-15-0943.
   PubMed Web of Science ®Google Scholar
• Wong, L., J. Zhou, D. Anderson, and R. A. Kratzke. 2002. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 38:131–36. doi:10.1016/S0169-5002(02)00178-2.
   PubMed Web of Science ®Google Scholar
• Xia, Z., D. Qiu, J. Deng, X. Jiao, R. Yang, Z. Sun, X. Wan, and J. Li. 2018. Methylation-induced downregulation and tumor-suppressive role of microRNA-98 in glioma through targeting Sal-like protein 4. Int. J. Mol. Med. 41:2651–59. doi:10.3892/ijmm.2018.3464.
   PubMed Web of Science ®Google Scholar
• Xiang, X.-J., J. Deng, Y.-W. Liu, L.-Y. Wan, M. Feng, J. Chen, and J.-P. Xiong. 2015. MiR-1271 inhibits cell proliferation, invasion and EMT in gastric cancer by targeting FOXQ1. Cell. Physiol. Biochem. 36:1382–94. doi:10.1159/000430304.
   PubMed Web of Science ®Google Scholar
• Xu, B., J. Liu, X. Xiang, S. Liu, P. Zhong, F. Xie, T. Mou, and L. Lai. 2018. Expression of miRNA-143 in pancreatic cancer and its clinical significance. Cancer Biother. Radiopharm. 33 (9):373–79. doi:10.1089/cbr.2018.2500.
   PubMed Web of Science ®Google Scholar
• Yang, C.-T., L. You, -C.-C. Yeh, J. W.-C. Chang, F. Zhang, F. McCormick, and D. M. Jablons. 2000. Adenovirus-mediated p14ARF gene transfer in human mesothelioma cells. J. Natl. Cancer Inst. 92:636–41. doi:10.1093/jnci/92.8.636.
   PubMed Web of Science ®Google Scholar
• Zhao, D., W. Han, X. Liu, D. Cui, and Y. Chen. 2017. Micro RNA‐128 promotes apoptosis in lung cancer by directly targeting NIMA‐related kinase 2. Thorac. Cancer 8:304–11. doi:10.1111/tca.2017.8.issue-4.
   PubMed Web of Science ®Google Scholar
• Zhou, H., Z. Huang, X. Chen, and S. Chen. 2017. miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers. Biomed. Pharmacother. 89:1453–61. doi:10.1016/j.biopha.2017.01.012.
   PubMed Web of Science ®Google Scholar
• Zhou, J.-G., H. Zhong, J. Zhang, S.-H. Jin, R. Roudi, and H. Ma. 2019. Development and validation of a prognostic signature for malignant pleural mesothelioma. Front. Oncol. 9:78. doi:10.3389/fonc.2019.00078.
   PubMed Web of Science ®Google Scholar